Treatment for Severe Hyperglycemia in Type 2 Diabetes

Immediate Treatment Strategy

The American Diabetes Association recommends immediately initiating combination therapy with metformin plus either a GLP-1 receptor agonist or SGLT2 inhibitor for patients with severe hyperglycemia (A1C 12%), and strongly consider adding basal insulin for rapid glucose toxicity resolution 1
Dual therapy should be initiated when A1C is ≥9% at diagnosis, and triple therapy or insulin should be considered when A1C exceeds this threshold substantially, as in the case of a patient with an A1C of 12% 2

Metformin should be initiated immediately unless contraindicated, as it is effective, safe, inexpensive, and may reduce cardiovascular events and death, according to the American Diabetes Association 1
A GLP-1 receptor agonist with demonstrated cardiovascular benefit should be added as the preferred second agent over insulin when possible, particularly if the patient has or is at high risk for cardiovascular disease, kidney disease, or heart failure, as recommended by the American Diabetes Association 1
Alternatively, an SGLT2 inhibitor with demonstrated cardiovascular benefit should be added, especially if heart failure or chronic kidney disease is present, as recommended by the American Diabetes Association 1

The American Diabetes Association explicitly states that treatment intensification should not be delayed for patients not meeting goals, and that significant glucose toxicity impairs beta-cell function and worsens insulin resistance, a reversible phenomenon that responds to aggressive glycemic control 1

The American College of Physicians recommends targeting an A1C of 7-8% for most patients, balancing microvascular risk reduction against hypoglycemia and treatment burden 3, 4, 5, 6
A1C should be reassessed in 3 months after treatment initiation, and further intensify therapy without delay if targets are not met, as recommended by the American Diabetes Association 1, 2

If cardiovascular disease, high CV risk, chronic kidney disease, or heart failure is present, prioritize a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit independent of A1C level, as recommended by the American Diabetes Association 1

The American Diabetes Association recommends avoiding stepwise monotherapy escalation at this A1C level, as the progressive nature of type 2 diabetes means monotherapy achieves target A1C <7% in only 25% of patients by 9 years, and instead recommends combination therapy 1
Insulin should not be delayed if the patient is symptomatic or if A1C remains >10% despite dual oral therapy, as recommended by the American Diabetes Association 2
A1C should not be targeted <6.5%, as this increases mortality risk without proven clinical benefit, according to the American College of Physicians 3, 4

A1C should be rechecked every 3 months until target is achieved, and at least twice yearly once stable at target, as recommended by the American Diabetes Association 1, 2
Patients should be assessed for hypoglycemia, medication adherence, and side effects at each visit, as recommended by the American Diabetes Association 1